Login to Your Account



Voyager ventures toward pivotal test of gene therapy for PD

By Michael Fitzhugh
Staff Writer

Wednesday, September 6, 2017

Voyager Therapeutics Inc.'s shares rose 24.7 percent on Wednesday as the company announced plans to embark on a pivotal phase II/III program testing its AAV2 gene therapy, VY-AADC-01, in advanced Parkinson's disease later this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription